У нас вы можете посмотреть бесплатно Itch & Urticaria: Mechanisms, Misconceptions & Hope_Episode 109 или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
In this episode, Prof. Torsten Zuberbier welcomes Prof. Gil Yosipovitch, world-renowned itch researcher and dermatologist at the University of Miami, for an in-depth discussion on the science of itch in urticaria, and why histamine isn’t the full story. 🔹 Why do antihistamines fail in up to 40% of urticaria patients? 🔹 What is MRGPRX2, and why is it such a promising target for future treatments? 🔹 How do pain and itch differ neurologically — and why is itch harder to ignore? 🔹 What role do topical steroids, JAK inhibitors, and GABAergic drugs play? Prof. Yosipovitch shares clinical and research insights on chronic itch mechanisms, highlighting how mast cells, nerves, cytokines, and ion channels interact to drive symptoms. The episode also explores why scratching can feel pleasurable, what makes urticaria itch unique, and how new therapies could revolutionize care. Join us for a cutting-edge conversation on the future of urticaria treatment — and why individualized care is the most powerful approach of all. Key Learnings from the Episode Chronic urticaria itch is not purely histaminergic — up to 40% of patients don’t respond to antihistamines, indicating other mechanisms. MRGPRX2 is a key non-histaminergic itch receptor found on mast cells and possibly nerve fibers — and is overexpressed in many itch disorders. Scratching itch activates pleasure centers in the brain, but urticaria patients scratch less deeply than those with atopic dermatitis. Cold and heat don’t always inhibit itch — responses vary across diseases and individuals, involving channels like TRPM8. Steroids and JAK inhibitors modulate both histaminergic and non-histaminergic itch pathways. Long-term steroid use is still widespread, especially in the US — but leads to serious comorbidities. Gabapentin and SNRIs like mirtazapine are valid add-on options in selected chronic itch patients. New biologics and mast cell-targeting drugs (like CKIT inhibitors) are on the horizon and may transform treatment. Each patient is unique — clinicians must move beyond dogma and adjust treatments to the individual, not just the guideline. Chapters 00:00 Understanding Itch: The Science Behind Chronic Pruritus 03:02 The Role of MRGPRX2 in Itch Mechanisms 05:53 Pain vs. Itch: Exploring the Neural Pathways 09:03 Individual Patient Experiences: The Complexity of Itch 11:48 Treatment Approaches: Antihistamines and Beyond 15:11 Emerging Therapies: The Future of Itch Management 🔻🔻🔻 If you’re interested in learning more about urticaria, don’t miss episodes of our podcast All Things Urticaria – available now on: 🎧 Spotify: https://open.spotify.com/show/7l1Vrfp... Apple Podcasts: https://podcasts.apple.com/de/podcast... Follow us on Instagram so you never miss an update:📲 @ga2lenetwork / 📲 @ucare_4u / ucare_4u For even more information, including clinical tools and updates relevant to physicians and healthcare professionals, visit our website:🌐 https://ucare-network.com/ 💡 Have ideas for future episodes?We welcome your input!Share your feedback and topic or speaker suggestions here:🔗 https://shorturl.at/rvK24 🎙️ Would you like to join us on an episode to discuss a topic related to urticaria or angioedema? Then please get in touch:📧 [email protected] Chapters 00:00 Understanding Chronic Urticaria: A Female Predominance 06:20 Pregnancy and Chronic Urticaria: What to Expect 11:36 Managing Urticaria During Pregnancy and Lactation 17:18 Fun Facts and Closing Thoughts